Participants
| Role | Name | HCID | Charge |
|---|
| Reactant | Pyridine | HCID 1049 | — |
| Reactant | Triethylamine | HCID 8471 | — |
| Reactant | Doxorubicin Hydrochloride | HCID 443939 | — |
| Solvent | Dichloromethane | HCID 6344 | — |
| Product | Doxorubicin | HCID 31703 | — |
Reaction Steps
3 g of mPEG-PLGA obtained above and 80 mg of p-nitrofluoroformate, a linker compound, were dissolved in 30 ml of methylene chloride. Then, 63 mg of pyridine was added to the solution, and reacted for 3 hours under a stream of nitrogen gas. And then, reaction product was precipitated by adding cold diethylether, filtered on a filter paper and dried under a reduced pressure. After dissolving 0.25 g of dried reaction product in 7.5 ml of dimethylformamide, 10 mg of doxorubicin-HCl(Sigma Chem. Co., U.S.A.) and 6.75 mg of triethylamine were added and reacted at room temperature for 24 hours under a nitrogen gas to obtain doxorubicin-conjugated micelle monomer(see: FIG. 2). The said micelle monomers were dispersed in 300 ml of triple distilled water to form doxorubicin-conjugated sustained release micelles, and free doxorubicin was removed by dialyzing the mixture 5 times against 3 L of triple distilled water each time. Doxorubicin-conjugated sustained release micelles were pelletized by ultracentrifugation, and freeze-dried after removing supernatant, and then, stored in the form of doxorubicin-conjugated micelle monomer.
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| Patent number | US06623729B2 |
|---|
| Source dataset | uspto-grants-2003_09 |
|---|
| ORD ID | ord-b0fc7084691d42c0aa052f0f232efca3 |
|---|
| Source note | uspto-grants-2003_09 |
|---|